Questions Raised by “Cost-Plus Pricing” in EU Pharmaceutical Law*
A Discussion on the Potential Cumulative Effects of Recent Policy Proposals Affecting Medicinal Product Development
- Keywords: EU pharmaceutical law, EU Life Sciences, pricing, cost-plus pricing, cost-based pricing, replacement compounding, off-label use, reimbursement
Abstract
Several stakeholders in the EU have called for a shift towards “cost-based” pricing for medicinal products, without thoroughly assessing the legal and economic implications. For many medicinal products, such a shift could turn the business case (net…[…]
